Fecha de recepción: 10/03/2018 – Fecha de aceptación: 25/04/2018
Gallego Úbeda M1, Tovar Pozo M1, Jiménez Rolando M2, Campos Fernández de Sevilla MA1
1 Farmacéutico Especialista en Farmacia Hospitalaria
2 Médico Especialista en Hematología y Hemoterapia
Hospital Universitario del Henares. Coslada. Madrid (España)
____
Correspondencia:
Marta Gallego Úbeda w Hospital Universitario del Henares w Avenida Marie Curie, s/n w 28822 Coslada – Madrid (España)
mgallego.hulp@salud.madrid.org
____
Summary
Liposomal cytarabine is used for the treatment (and prophylaxis) of central nervous system (CNS) involvement in patients with lymphomas. A 62-year-old female patient with diffuse large B-cell lymphoma stage IV with CNS, infiltration receives intrathecal liposomal cytarabine. Two and a half months after the last administration of the drug, cerebrospinal fluid (CSF) analysis reveales rounded images, without nucleus and similar in size to leukocytes. The liposomal cytarabine formulation is similar in size and physical features to white blood cells. Care should be taken by clinicians in the interpretation of CSF results of patients previously treated with the drug. The liposome vesicles that contained cytarabine could be observed in CSF as leukocytes or microorganisms and could assist clinicians on wrong decision-making.
Key Words: Liposomal cytarabine, leukocytes, cerebrospinal fluid, lymphoma, central nervous system.
____
Download PDF: Liposomas de citarabina en líquido cefalorraquídeo tras la administración del fármaco. A propósito de un caso